No Platelet Rich Plasma

Phase 1Small molecule

DDamascus University

No Platelet Rich Plasma is one of 7 small molecule programs targeting Bone Resorption. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone ResorptionActive, not recruiting

Bone ResorptionPhase 1

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Bone Resorption

#DrugCompanyPhaseTrials

Fosamax

OOrganon and Co

Approved

1 2

Zometa

Pfizer

Phase 3

1 3

Prolia

Amgen

Preclinical

1 4

Platelet Rich Plasma

ZZagazig University

Phase 1

1 5

Humira

CCelltrion

Preclinical

2 6

Veverimer

RRenibus Therapeutics, Inc.

Phase 1

1 7

No Platelet Rich Plasma

DDamascus University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Resorption1 trial

Using Platelet Rich Plasma in Reducing Alveolar Bone Resorption During Rapid Maxillary Expansion

Completed·—·Phase 1·NCT03028038·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for No Platelet Rich Plasma. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — No Platelet Rich Plasma compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for No Platelet Rich Plasma. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Damascus University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDamascus University

No Platelet Rich Plasma

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Resorption1 trial

References

Drug Info

Quick Facts

Related News